Drug intelligence / Profile preview

ACD004

Development stage: Unknown
Lead developer: Nestlé
Administration: Oral

Overview

ACD004 is a polymeric enteral nutritional formula developed by Nestle. It is designed for the treatment of Crohn's disease, particularly in pediatric patients. The formula is lactose-free, uses casein as its protein source, and is notably rich in Transforming Growth Factor Beta (TGF-beta). Clinical studies have shown that ACD004 can induce clinical remission and improve the quality of life in children with active Crohn's disease by influencing the disease process and reducing inflammation, although improvement in quality of life may not always parallel mucosal healing.

Targets

TGFBR (TGF-beta receptor)

Beyond the preview

Go deeper on ACD004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACD004.

Explore the full profile